Wegovy 0.5mg Not Working — What This Usually Means

Why 0.5mg is rarely the dose that changes things

Wegovy's titration schedule exists for a specific reason: the gastrointestinal side effects of semaglutide (nausea, loose stools, reflux) are dose-dependent. Starting low and increasing slowly lets your body adapt. The 0.25mg and 0.5mg steps are part of that adjustment window, not the phase where the medicine is expected to deliver its full effect on appetite and weight.

The STEP 1 trial published in the New England Journal of Medicine ran to 68 weeks at 2.4mg (the maintenance dose) and reported around 15% average body-weight reduction. The 0.5mg phase is a few weeks long and sits well below that ceiling. Expecting significant weight loss at this stage sets a benchmark the trial data never suggested.

That said, some people do notice a small but real reduction in hunger even at 0.5mg. If you're one of them, that's a useful early signal. If you're not, it doesn't predict how you'll respond at higher doses. The experience at the very first dose is similarly variable, the pattern often only becomes clearer over the full titration.

The factors worth weighing before drawing a conclusion

Before deciding your Wegovy 0.5mg isn't working, it's worth separating a few things. First: how long have you been at 0.5mg? The standard titration holds each dose for around four weeks. If you're two weeks in, you're not yet at the point where an honest assessment makes sense.

Second: are side effects making it hard to eat normally? Nausea can suppress appetite mechanically, some people lose weight at starter doses partly because eating feels uncomfortable. Others have minimal side effects and equally minimal appetite change. Neither tells you what 1mg or 1.7mg will do.

Third: lifestyle factors matter more at lower doses than at maintenance. Semaglutide is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them. At 0.5mg, those factors carry more of the load. If eating habits haven't shifted much and the dose hasn't yet reduced hunger, the combination may need time. For a broader look at how results typically evolve across the full schedule, the Wegovy dose guide sets out what each stage is designed to do.

Fourth (and this matters) some people find that a dose that felt ineffective at week two feels meaningfully different by week four, once the steady-state blood level has built. Semaglutide has a long half-life; it takes a few weeks to accumulate. Timing your assessment at the right point matters, in the same way that a quiet week mid-month or just before payday might make changes to routine feel more obvious than they otherwise would.

When to raise it with your prescriber before the next titration step

There are situations where waiting it out isn't the right call. If you're experiencing side effects severe enough to affect your daily life (persistent vomiting, significant dehydration, or symptoms you can't manage) contact your prescriber promptly rather than continuing to the next dose in hope. The NHS semaglutide medicines page sets out which symptoms warrant urgent attention.

Equally, if you were previously on a higher Wegovy dose and have stepped back down due to supply or a break in treatment, 0.5mg will likely feel different from when you first titrated through it. A prescriber familiar with your history can help judge the right pace for retitration. Our clinical team at nume, sorry, at the prescribing team reviews this at every stage of treatment.

The decision most people face at 0.5mg isn't whether to stop. It's whether to continue as planned, discuss slowing the titration to manage side effects, or flag a specific concern. That's a conversation with a prescriber, not a judgement you need to make alone. If you're mid-treatment and want a clinical review of where you stand, what happens if the situation continues at higher doses is also worth understanding ahead of time.

What comes next in the titration, and when the evidence kicks in

The step from 0.5mg to 1mg is where many people first report a noticeable shift in hunger. Not everyone, but a meaningful proportion. From 1mg upward, you're moving into the dose range that begins to approach the therapeutic window studied in trials. The 1.7mg and 2.4mg doses represent the later stages where the bulk of the trial evidence sits.

If the 0.5mg phase has been tolerable, that's actually useful information: it suggests your system can handle the medicine and that dose increases are likely to proceed safely. If side effects have been notable, your prescriber may want to hold at 0.5mg a little longer before stepping up, and if you want to understand what to do when 1mg doesn't seem to be working, that's a question worth having answered before you reach that stage.

For context on how the whole picture fits together, the Wegovy overview page covers the licensed indications, the trial background and how the titration schedule was designed. And if questions about the private cost of continuing treatment are on your mind, the Wegovy cost page sets out what's included in a private prescription. Treatment is a prescription-only medicine; every step requires clinical oversight, and a prescriber decides what's appropriate for your situation.